Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? Abbott trades at a 18x forward P/E with $7.4B in free cash flow, while Intuitive Surgical commands a 39x multiple backed by zero debt and 20% revenue growth.
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.
These 3 Dividend Stocks Yield Less Than 10-Year Treasuries Over 5%. Here's Why They Are Better Buys Anyway. Treasuries pay more today, but these three healthcare dividend payers offer something Treasuries can't: growth in both the payout and the stock.
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? Intuitive Surgical is beating estimates and raising margins while its installed base keeps expanding. Abbott is executing steadily across a diversified portfolio but growing at a more measured pace.
3 High-Yielding Dividend Stocks That Are No-Brainer Buys for Retirees and Risk-Averse Investors These quality, low-volatility stocks yield between 2.4% and 3.1%, and have been raising their payouts for decades.
Abbott Laboratories vs. Intuitive Surgical: Recent Quarterly Revenue Trends Reveal a Classic Investing Truth Abbott leads in absolute revenue, but Intuitive Surgical's growth rate tells a different story over the past eight quarters.
3 Dividend Stocks to Buy and Hold for 10 Years They have a knack for increasing their dividends even when facing challenges.
Why Wall Street Is Becoming Even More Bullish About This Dividend King Analysts keep raising their price targets on this 54-year dividend raiser. Here are the reasons behind the newfound confidence.
SCHD's Stunning Reversal: Schwab's Flagship Dividend ETF Is Up 29% and Climbing Given what's going on in the world and in the market, perhaps it's natural that SCHD is surging.
If a Stock Market Crash Is Coming, Investors Will Want to Own This Dividend King Worried about a pullback? This Dividend King pairs a 54-year streak with catalysts that could provide income even if the market crashes.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.
3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King) Owning these dividend stocks could be a simple way to make money over the long term.
